5-147828020-A-G
Position:
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PVS1PP5
The NM_001379610.1(SPINK1):c.194+2T>C variant causes a splice donor change. The variant allele was found at a frequency of 0.000114 in 1,609,104 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00016 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00011 ( 0 hom. )
Consequence
SPINK1
NM_001379610.1 splice_donor
NM_001379610.1 splice_donor
Scores
3
3
1
Splicing: ADA: 0.9997
2
Clinical Significance
Conservation
PhyloP100: 4.35
Genes affected
SPINK1 (HGNC:11244): (serine peptidase inhibitor Kazal type 1) The protein encoded by this gene is a trypsin inhibitor, which is secreted from pancreatic acinar cells into pancreatic juice. It is thought to function in the prevention of trypsin-catalyzed premature activation of zymogens within the pancreas and the pancreatic duct. Mutations in this gene are associated with hereditary pancreatitis and tropical calcific pancreatitis. [provided by RefSeq, Oct 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, LoF is a know mechanism of disease, No cryptic splice site detected. Exon removal results in frameshift change.
PP5
Variant 5-147828020-A-G is Pathogenic according to our data. Variant chr5-147828020-A-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 132142.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=2, not_provided=1, Uncertain_significance=1, Pathogenic=9}. Variant chr5-147828020-A-G is described in Lovd as [Pathogenic]. Variant chr5-147828020-A-G is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SPINK1 | NM_001379610.1 | c.194+2T>C | splice_donor_variant | ENST00000296695.10 | NP_001366539.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SPINK1 | ENST00000296695.10 | c.194+2T>C | splice_donor_variant | 1 | NM_001379610.1 | ENSP00000296695 | P1 | |||
SPINK1 | ENST00000510027.2 | c.196T>C | p.Ter66ArgextTer4 | stop_lost | 3/3 | 3 | ENSP00000427376 | |||
SPINK1 | ENST00000505722.1 | n.109+2T>C | splice_donor_variant, non_coding_transcript_variant | 2 |
Frequencies
GnomAD3 genomes AF: 0.000158 AC: 24AN: 152208Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
24
AN:
152208
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000313 AC: 78AN: 248892Hom.: 0 AF XY: 0.000253 AC XY: 34AN XY: 134536
GnomAD3 exomes
AF:
AC:
78
AN:
248892
Hom.:
AF XY:
AC XY:
34
AN XY:
134536
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000109 AC: 159AN: 1456778Hom.: 0 Cov.: 29 AF XY: 0.000109 AC XY: 79AN XY: 724932
GnomAD4 exome
AF:
AC:
159
AN:
1456778
Hom.:
Cov.:
29
AF XY:
AC XY:
79
AN XY:
724932
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000158 AC: 24AN: 152326Hom.: 0 Cov.: 32 AF XY: 0.000188 AC XY: 14AN XY: 74496
GnomAD4 genome
AF:
AC:
24
AN:
152326
Hom.:
Cov.:
32
AF XY:
AC XY:
14
AN XY:
74496
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
3
ExAC
AF:
AC:
35
Asia WGS
AF:
AC:
3
AN:
3478
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:14Uncertain:1Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Hereditary pancreatitis Pathogenic:5Uncertain:1Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 26, 2024 | This sequence change affects a donor splice site in intron 4 of the SPINK1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs148954387, gnomAD 0.3%), and has an allele count higher than expected for a pathogenic variant. Disruption of this splice site has been observed in individual(s) with chronic pancreatitis (PMID: 15980664, 23017645, 26632706). ClinVar contains an entry for this variant (Variation ID: 132142). Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 18978175, 26719302). For these reasons, this variant has been classified as Pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Dec 14, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Human Genetics, Inc, Center for Human Genetics, Inc | Nov 01, 2016 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 13, 2021 | The c.194+2T>C intronic pathogenic mutation results from a T to C substitution two nucleotides after coding exon 3 in the SPINK1 gene. This alteration occurs at the 3' terminus of the SPINK1 gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 16 amino acids of the protein. The exact functional effect of this alteration is unknown; however, the impacted region is critical for protein function (Ambry internal data). This alteration was first reported in an individual with chronic pancreatitis (Witt H et al. Nat. Genet., 2000 Jun;25:213-6). A functional study found this mutation causes a splicing defect that significantly diminishes SPINK1 expression at the mRNA level and results in diminished trypsin inhibitor secretion (Kereszturi E et al. Gut, 2009 Apr;58:545-9). This mutation has been seen in individuals affected with idiopathic, familial, alcoholic, autoimmune and tropical chronic pancreatitis (Kereszturi E et al. Gut, 2009 Apr;58:545-9; Chang MC et al. J Gastroenterol Hepatol, 2014 Dec;29:2038-42; Cho SM et al. Ann Lab Med, 2016 Nov;36:555-60; Tang XY et al. Dig Liver Dis, 2020 02;52:143-148). This alteration has also been identified in individuals diagnosed with breast and/or pancreatic cancer (Yang X et al. PLoS One, 2015 Apr;10:e0125571; Boortalary T et al. Pancreas, 2018 Apr;47:e24-e25). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 29, 2018 | Variant summary: SPINK1 c.194+2T>C is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. 5/5 computational tools predict a significant impact on normal splicing. These predictions are supported by multiple functional studies, Kume_2006 and Kereszturi_2009, found the variant to significantly affect splicing. Multiple publications have cited the variant in affected individuals diagnosed with chronic pancreatitis, predominantly of Asian origin. Multiple clinical diagnostic laboratories have ClinVar submissions (after 2014) classifying the variant as "pathogenic." GeneReviews, a well-established database, classifies the variant as "pathogenic." Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:5
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | May 01, 2024 | SPINK1: PVS1:Strong, PS4:Moderate, PM2:Supporting, PS3:Supporting - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 13, 2020 | The SPINK1 c.194+2T>C variant (rs148954387) has been reported in the literature in numerous individuals diagnosed with chronic pancreatitis (Cho 2016, Kume 2006, Witt 2000, Zou 2018) and is one of the most common pathogenic variants in East Asian individuals affected with pancreatitis (Cho 2016, Zou 2018). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 132142), and it is found in the general population with an overall allele frequency of 0.03% (85/280290 alleles) in the Genome Aggregation Database. This variant abolishes the canonical splice donor site of intron 4, which is likely to disrupt gene function. Indeed, functional studies indicate a significant reduction of mRNA levels, skipping of exon 3, and undetectable levels of the SPINK1 protein (Kereszturi 2009, Kume 2006, Zou 2016). Based on available information, the c.194+2T>C variant is considered to be pathogenic. References: Cho SM et al. PRSS1, SPINK1, CFTR, and CTRC Pathogenic Variants in Korean Patients With Idiopathic Pancreatitis. Ann Lab Med. 2016 Nov;36(6):555-60. Kereszturi E et al. Minigene analysis of intronic variants in common SPINK1 haplotypes associated with chronic pancreatitis. Gut. 2009; 58(4):545-9. Kume K et al. [-215G>A; IVS3+2T>C] mutation in the SPINK1 gene causes exon 3 skipping and loss of the trypsin binding site. Gut. 2006; 55(8):1214. Witt H et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet. 2000; 25(2):213-6. Zou WB et al. Clarifying the clinical relevance of SPINK1 intronic variants in chronic pancreatitis. Gut. 2016 May;65(5):884-6. Zou WB et al. SPINK1, PRSS1, CTRC, and CFTR Genotypes Influence Disease Onset and Clinical Outcomes in Chronic Pancreatitis. Clin Transl Gastroenterol. 2018 Nov 12;9(11):204. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 21, 2020 | - - |
Hereditary pancreatitis;C1842402:Tropical pancreatitis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Diabetes mellitus Pathogenic:1
Pathogenic, no assertion criteria provided | research | Constantin Polychronakos Laboratory, The Research Institute of the McGill University Health Centre | - | PVS1 PS1 PP2 - |
SPINK1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 20, 2024 | The SPINK1 c.194+2T>C variant is predicted to disrupt the GT donor site and interfere with normal splicing. This variant has been reported as causative for SPINK1-related disorders, including chronic pancreatitis, and functional studies support its pathogenicity (Witt et al. 2000. PubMed ID: 10835640; Kereszturi et al. 2008. PubMed ID: 18978175; Sun et al. 2015. PubMed ID: 26632706). This variant is reported in 0.33% of alleles in individuals of East Asian descent in gnomAD. Variants that disrupt a consensus splice donor site in SPINK1 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Chronic pancreatitis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2017 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
D;N
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DL_spliceai
Position offset: 2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at